TMS Clinical Trials

Size	Price	Qty
5mg	USD 147

Clinical Trials

Several clinical trials are evaluating therapeutic interventions across neurodegenerative, psychiatric, and cerebrovascular conditions, specifically targeting Parkinson's disease, major and persistent depressive disorders, and stroke. Ranging from Phase 1 and Phase 2 protocols to studies categorized as Not Applicable, all entries are currently in a not yet recruiting status. Sponsored by entities including the VA Office of Research and Development, the University of Pennsylvania in conjunction with the National Institutes of Health, and UMC Utrecht, these investigations focus on neuroplasticity, subgenual cingulate stimulation, and post-stroke motor recovery.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06231563	Not yet recruiting	Parkinson?s Disease	VA Office of Research and Development	2024-07-01	Phase 2
NCT06266390	Not yet recruiting	Depression\|Major Depressive Disorder\|Persistent Depressive Disorder	University of Pennsylvania\|National Institutes of Health (NIH)	2024-06-30	Phase 1
NCT06381388	Not yet recruiting	Stroke	Jord Vink\|UMC Utrecht	2024-06-01	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the TMS product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

TMS ((E)-2,3',4,5'-tetramethoxystilbene) acts as a potent, selective, and competitive human cytochrome P450 1B1 (CYP1B1) inhibitor with an IC50 of 6 nM, effectively blocking CYP1B1-mediated metabolic activation of endogenous and exogenous substrates. By preventing downstream procarcinogen bioactivation and cellular oxidative stress, this target inhibition provides potential clinical relevance for modulating neuroinflammatory and metabolic pathomechanisms studied in clinical trials for Parkinson's disease, depression, and stroke.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).